Precision for Medicine Broadens Cancer Trial Offering With ACT Oncology Buy – FierceCRO
Chad Clark and Pat Devitt speak with Ben Adams from FierceBiotech on the acquisition of ACT Oncology.
Precision for Medicine to Acquire ACT Oncology
Establishes leading platform for Precision Medicine Oncology Research
Bethesda, Md. and Flemington, N.J., March 22, 2016 – Precision for Medicine, part of the Precision Medicine Group, announced today that it has executed a binding agreement to acquire ACT Oncology, the leading contract research organization (CRO) specializing exclusively in the field of oncology. ACT Oncology provides drug development services focused on the design and execution of clinical trials on behalf of innovative life sciences companies and not-for-profit patient organizations.
R&D Spending by Drug Companies – Pharmaceutical Compliance Monitor
By Ilyssa Levins
R&D Spending by Drug Companies
You may have read my February 2016 PCM article that proposed a six-step plan to deflect criticism about pharmaceutical drug costs. I provided hard data to support the value of our industry and will now continue to expand upon our value by addressing the significant role of America’s biopharmaceutical companies in bringing new medicines to patients. (more…)
Commentary: Payer Reaction To FDA Safety Warnings — What Pharma Manufacturers Need To Know
Jeremy Schafer examines payer reaction to FDA warnings in Pharmaceutical Commerce.
Precision for Medicine Transforms Big Data into Actionable Information – BioIT World
BioIT World’s Paul Nicholas examines Precision for Medicine’s new PATH immuno-analytics platform.